Evidence map›Paper›PMID 39802251›Full record

ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2025

Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study.

Bhupesh Dewan, Sanjaykumar Navale, Siddheshwar Shinde, Janaki Chaudhary

Abstract read
In one paragraph

Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bhupesh DewanZuventus Healthcare Limited, Mumbai, Maharashtra, India.ORCID https://orcid.org/0000-0002-0367-3142
Sanjaykumar NavaleMedical Services, Zuventus Healthcare Limited, Mumbai, Maharashtra, India.ORCID https://orcid.org/0009-0007-4419-810X
Siddheshwar ShindeMedical Services, Zuventus Healthcare Limited, Mumbai, Maharashtra, India.ORCID https://orcid.org/0000-0002-4790-9161
Janaki ChaudharyClinical Research Associate, Zuventus Healthcare Limited, Mumbai, Maharashtra, India.ORCID https://orcid.org/0009-0004-1959-6454

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim and background: To assess the efficacy and safety of Ibutilide infusion for cardioversion of atrial fibrillation (AF) or flutter (AFL) to sinus rhythm. Materials and methods: This open-label, multicenter phase IV study was conducted at six sites across India. The study enrolled 120 patients (108 with AF, 12 with AFL), each receiving up to two, 10-minute intravenous doses of 1.0 mg Ibutilide. The primary endpoints were the proportion of patients achieving cardioversion and the mean time taken to achieve cardioversion. Secondary endpoints included the proportion of patients maintaining sinus rhythm at 24 hours and the incidence of adverse events. Results: The cardioversion rate at 4 hours post-Ibutilide infusion among 120 patients was 65.83% ( Conclusion: Ibutilide was found to be effective and well-tolerated for rapid restoration of sinus rhythm in patients with AF or AFL. Clinical Trial Registry of India: CTRI/2018/01/011248. How to cite this article: Dewan B, Navale S, Shinde S, Chaudhary J. Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study. Indian J Crit Care Med 2025;29(1):45-51.

Indexed as

Atrial fibrillationAtrial flutterCardioversionIbutilide

Identifiers

PMID39802251
PMCPMC11719548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.